3 results about "Receptor binding sites" patented technology

Provided herein are antibody construct molecules comprising (i) an Fc receptor binding site, (ii) an antigen-binding site and (iii) a spacer moiety located between (i) and (ii), wherein the spacer moiety serves to increase the distance between (i) and (ii) so as to reduce the agonistic activity of the molecule as compared to the antibody variant that lacks (iii). Disclosed are various antibodies that can be de-agonized by introduction of the spacer moiety. Of specific interest are agonistic check point targeting antibodies that are de-agonized by introduction of the spacer moiety.

The present disclosure relates generally to binding proteins comprising an antigen binding site, a T cell receptor binding site, and a T cell costimulatory molecule binding site. The disclosure also relates to pharmaceutical compositions comprising such binding proteins, nucleic acid molecules encoding such binding proteins and vectors comprising such nucleic acid molecules. The disclosure also relates to methods of treating a disorder or condition using such binding proteins and pharmaceutical compositions, binding proteins and pharmaceutical compositions for use in the treatment of a disorder or condition, and the use of such binding proteins and pharmaceutical compositions for the manufacture of a medicament for the treatment of a disorder or condition.

The present invention relates to chimeric GT-B type glycosyltransferases, comprising an N-terminal acceptor binding site, a C-terminal donor binding site, and a linker loop linking the N-terminal acceptor binding site and the C-terminal donor binding site, wherein (i) the N-terminal acceptor binding site domain comprises or consists of an amino acid sequence having at least 80 %, preferably at least 90 %, more preferably 100 % sequence identity to the amino acid sequence set forth in SEQ ID NO: 1; and / or (ii) the linker loop comprises or consists of an amino acid sequence having at least 80 %, preferably at least 90 %, more preferably 100 % sequence identity to the amino acid sequence set forth in SEQ ID NO: 4; and / or (iii) the C-terminal donor binding site domain comprises or consists of an amino acid sequence having at least 80 %, preferably at least 90 %, more preferably 100 % sequence identity to the amino acid sequence set forth in SEQ ID NO: 2 or comprises or consists of an amino acid sequence having at least 80 %, preferably at least 90 %, more preferably 100 % sequence identity to the amino acid sequence set forth in SEQ ID NO: 3; and / or (iv) the C-terminal donor binding site domain is a chimeric C-terminal donor binding site domain comprising a first amino acid sequence derived from a glycosyltransferase distinct from the glycosyltransferase from which the N-terminal acceptor binding site domain is derived, and a second amino acid sequence derived from the same glycosyltransferase as the N-terminal acceptor binding site domain, wherein the first amino acid sequence is linking the linker loop and the second amino acid sequence; to nucleic acid molecules encoding such GT-B type glycosyltransferases; to a method of production of such chimeric GT-B type glycosyltransferases; to a method of production of polysaccharides using such chimeric GT-B type glycosyltransferases and the polysaccharides obtainable by such a method; to polysaccharides defined by formula (I); to compositions comprising such polysaccharides; and further to uses of such polysaccharides as thickening and / or gelling agents and / or as rheology modifiers and / or as 3D-printing inks and / or coatings.